Hansoh Pharma's aumolertinib approved in UK for lung cancer

Hansoh Pharmaceutical Group Company Limited (HKEX: 3692) announced that its innovative drug, Aumolertinib Mesilate Tablets (Aumseqa®), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for marketing. Aumseqa® is indicated as monotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Aumolertinib Mesilate Tablets has already been approved for four indications in China, with another NDA under review for first-line treatment of specific NSCLC patients.